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Background: Metformin has been associated with lower breast cancer risk and 
improved outcomes in observational studies. Multiple biologic mechanisms have been 
proposed, including a recent report of altered sex hormones (SHs). We evaluated the 
effect of metformin on SHs in MA.32, a phase III trial of nondiabetic BC subjects 
randomized to metformin or placebo. 
Methods: We studied the subgroup of post-menopausal hormone receptor negative BC 
subjects not receiving endocrine treatment who provided fasting blood at baseline and at 
6 months after randomization. Sex hormone binding globulin (SHBG), bioavailable 
testosterone (BT) and estradiol levels were assayed using ECLIA 
(electrochemiluminescense immunoassay). Change from baseline to 6 months between 
study arms was compared using Wilcoxon sum rank tests and regression models. 
Results: 312 women were eligible (141 metformin vs 171 placebo); the majority of 
subjects in each arm had T1/2, N0, HER2 negative BC and had received (neo)adjuvant 
chemotherapy. Mean age ± SD was 58.1±6.9 vs 57.5±7.9 years, mean BMI was 
27.3±5.2 vs 28.9±6.4 kg/m2 for metformin vs placebo respectively. Median estradiol 
decreased between baseline and 6 months on metformin vs placebo (-5.7 vs 0 pmol/L; 
p<0.001) in univariable analysis and after controlling for baseline BMI and BMI change 
(p<0.001). There was no change in SHBG or BT. 
Conclusion: Metformin lowered estradiol levels, independent of BMI. This observation 
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Metformin has garnered attention as a potential anti-cancer agent across a range 
of cancers, including breast cancer (BC); potential effects on BC outcomes are being 
studied in CCTG MA.32, an ongoing Phase 3 adjuvant trial comparing metformin 850 
mg bid vs placebo bid  (each given for 5 years) in subjects receiving standard breast 
cancer therapy.1 It has been postulated that metformin may impact BC directly (for 
example, via intra-tumoral LKB1 mediated AMPK activation leading to suppression of 
mTORC1 signaling) and/or indirectly (for example, via inhibition of hepatic 
gluconeogenesis with subsequent reduction in circulating insulin levels, reducing 
PI3K/Akt/mTOR signaling in cancer cells expressing the insulin receptor).2 Data from 
neoadjuvant clinical trials have provided some support for both direct and indirect 
mechanisms.3,4 Recent research has suggested metformin may also act indirectly via an 
effect on sex hormones (SHs), although findings have been inconsistent. 5-8 
SHs are of relevance to both BC risk and prognosis, particularly in post-
menopausal women. 9-12 In a case control study nested in the Women´s Healthy Eating 
and Living Study (WHEL), BC patients who recurred had higher levels of estrogens 
than those who did not recur (22.7 vs 10.8 pg/mL; p = 0.05).10 The importance of SHs 
in hormone receptor positive BC is highlighted by the therapeutic effectiveness of 
aromatase inhibitors, which reduce estrogen production in postmenopausal women.    
Campagnoli et al.5,6 studied the effect of metformin (1500 mg/day vs 1000 
mg/day after a one-month run-in of 1000 mg/day) on SHs in 96 non diabetic post-
menopausal BC patients (50% of whom were on tamoxifen) with pre-baseline 
testosterone above 0.28 ng/ml. Metformin reduced estradiol (-38%; p< 0.02) and free 
testosterone (-29%; p< 0.01); these differences remained statistically significant after 
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Patterson et al.7 used a 2 X 2 factorial design to randomize 313 overweight or 
obese postmenopausal BC patients to  metformin 1500mg/daily vs placebo and  a 
lifestyle weight loss program vs control. Metformin (vs placebo) lowered estradiol (-
10%, 95% CI, -18.5 to -1.5%) and testosterone (-9.5%, 95%CI, -15.2% to -3.8%) and 
increased sex hormone binding globulin (SHBG) (+7.5%; 95% CI, 2.4-12.6%) levels. 
However, estradiol appeared to be reduced only in those receiving both metformin and 
the lifestyle intervention.8 In a final study conducted in 382 overweight, glucose-
intolerant patients without BC enrolled onto the Diabetes Prevention Program (DPP),13 
metformin had no impact on SHBG, estradiol, testosterone or dehydroepiandrosterone.  
 We investigated the SHs in postmenopausal women with hormone receptor 
negative BC (selected to avoid use of endocrine therapies that may impact SHs) 
enrolled onto the MA.32 trial. We also explored effects of the minor allele (C) of the 
rs11212617 single nucleotide polymorphism (SNP) that has been associated with 
greater metabolic response to metformin in type 2 diabetes,14 and increased pathologic 




We conducted a sub-study of patients enrolled onto the MA.32 randomized phase III 
clinical trial.1 The focus on SHs was not part of the original trial protocol; as evidence 
of an effect of metformin on SHs emerged, this work was approved by the trial steering 
committee as part of a priori plan to investigate potential mechanisms of metformin 
action. The primary objective of this sub-study was to compare change in levels of pre-
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months between metformin and placebo arms; if a difference between study arms was 
found, secondary objectives were to explore two possible pathways of metformin action 




The Canadian Cancer Trials Group (CCTG) MA.32 Clinical Trial (Clinical Trials.gov 
identifier: NCT01101438 and EudraCT number: 2011-005230-18)1 is a phase III, 
double blind trial that randomly assigned 3649 non-diabetic patients with T1c-3 (any 
ER, PgR, HER2), N0-3, M0 BC who received standard treatment to receive metformin 
850 mg po bid or placebo po bid for 5 years (including a 4-week ramp-up of one tablet 
per day) between 2010 and 2013. In May 2012, after 2382 women were enrolled, 
eligibility criteria were amended:  those with T1cN0 disease had to have triple negative 
BC (ER negative, PgR negative, HER2 negative) to enter the trial and  those  with T2 
N0 BC were eligible only if they had at least one of the following risk factors: 
histologic grade III, presence of lymphovascular invasion, negative estrogen (ER) and 
progesterone (PgR) receptors, HER2 positivity, Oncotype Recurrence Score ≥ 25 or Ki-
67 over 14%. Exclusion criteria included fasting glucose > 7.0 mmol/L (126 mg/dL), 
known diabetes or current use of diabetes medication, hypersensitivity to or intolerance 
of metformin, history of lactic acidosis, participation in trials of weight loss or exercise 
interventions, recurrence of BC or prior BC, excessive alcohol intake, or marked 
hepatic, kidney, or cardiac dysfunction. 
All patients provided written informed consent to participate in the MA.32 clinical trial 
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The SH sub-study was conducted in post-menopausal women (to avoid cyclical changes 
in endogenous hormone production) with hormone receptor negative BC, who were not 
receiving endocrine treatment (to avoid effects of hormonal agents used to treat BC). 
Post-menopausal was defined as prior bilateral oophorectomy or > 12 months since last 
menses without prior hysterectomy. Baseline blood was obtained before study treatment 
was initiated; patients were required to be on study treatment at the time of the six-
month blood draw.  
At baseline, information was collected on age and tumor characteristics (stage, 
histological type, immunohistochemical profile) and treatment. Height and weight were 
measured at baseline, and weight at six months. Body mass index (BMI) was calculated 
as weight/height2 (kg/m2). 
Blood Assays 
The serum samples were collected into heparin tubes, aliquoted and stored at -80C 
after an overnight fast of at least 12 hours. Paired specimens from each patient were 
retrieved, thawed and analyzed in the same batch by technicians blinded to patient 
treatment. The biologically most active estrogen (17β Estradiol), SHGB and total 
testosterone levels were determined using competitive ECLIA 
(electrochemiluminescense immunoassay) on cobas e602 and insulin using Roche 
ECLIA, catalogue #12017547122, at a CAP/CLIA accredited clinical laboratory (Mount 
Sinai Services). Intra-assays coefficients of variability were 7%, 2.4%, 4.6.% and 3%, 
respectively. Albumin was assayed to allow calculation of BT from total testosterone, 
SHBG and albumin. The automated platform cobas e602 provides a lower detection 
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measurement range for SHBG was 0.350 nmol/L to 200 nmol/L (defined as the limit of 
detection and the maximum of the master curve). 
 
SNP Analysis 
Genomic DNA was extracted from whole blood and samples were genotyped for the 
rs11212617 SNP (Chr11(GRCh38):g.108412434C>A) at The Centre for Applied 
Genomics, The Hospital for Sick Children, Toronto, Canada using a QIAsymphony 
magnetic bead DNA extractor (Qiagen, Germany) and a TaqMan PCR assay with dual-
label MGB probes (Applied Biosystems™, ThermoFisher Scientific, Waltham, MA, 
USA).   
 
Statistical Analysis 
Patient and tumor characteristics at diagnosis were summarized. Since the distributions 
of the SHs were skewed, medians were used as measures of central tendency and 25th 
and 75th percentiles as measures of dispersion. Descriptive summaries were tabulated 
for baseline and change in the SH levels, where change was calculated as the six-month 
value minus the baseline value for each patient. Estradiol, testosterone and SHBG were 
all considered equally important main outcomes.  
The pre-specified method of comparing the degree of change between arms was 
the Wilcoxon rank-sum test. Ten baseline and seven month 6 SHBG results (3%) were 
recorded as >200 nmol/L; these were replaced by 200 nmol/L. Overall, 25% of baseline 
and 33% of month 6 estradiol assay results were below the assay's limit of detection 
(LOD); change calculations, summary statistics and the Wilcoxon test were performed 
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performed an additional sensitivity analysis using survival methods for left-censored 
data. The data can be analyzed using right-censored survival methods (product limit 
estimator and the log-rank test) by subtracting the left-censored observations from a 
large constant, a process called "flipping".17 With only one point of censoring (the 
LOD), the product-limit method simplifies to the construction of exceedance curves, 
where for a defined set of levels e* one calculates the proportion of patients in each arm 
whose estradiol at month 6 was higher than each of the e*.  
For SHs with a statistically significant difference between arms, we explored 
two possible pathways of metformin action by fitting multivariable linear regression 
models controlling for baseline BMI and BMI change, and  insulin change. This was 
done by log-transforming all continuous variables to reduce skewness and then fitting a 
model with SH change as dependent variable and with treatment status and baseline 
assay level as explanatory variables.  Baseline and change in BMI, or insulin change, 
was then added to this model. We back-transformed the coefficient for treatment status 
to get the percent difference between the metformin and placebo arms. Finally, using a 
regression model for change that included an interaction term for treatment by SNP, 
coded as any C vs AA, we examined whether a metformin effect was restricted to 
patients with the C allele of the rs11212617 SNP. Reported p-values are nominal and 
not adjusted for multiple comparisons. 
A priori power calculations indicated we had 80% power with 150 patients per 
arm to detect differences in change between the arms of 12%, 14% and 20% for SHBG, 
testosterone and estradiol respectively, using a two-sided alpha of 0.05 without 












Three hundred and twelve women were eligible based on post-menopausal status, 
ER/PgR negative invasive BC not receiving hormonal treatment and availability of 
blood at baseline and 6 months (the latter on study treatment), 141 on metformin and 
171 on placebo arm (Fig. 1 - Consort Diagram). Patient and tumor characteristics are 
shown in Table 1. At baseline mean age (± standard deviation) was 58.1±6.9 vs 
57.5±7.9 years, mean weight 72.6±14.1 vs 76.6±17.5 kg and mean BMI 27.3±5.2 vs 
28.9±6.4 kg/m2 in metformin vs placebo arms, respectively. Combining clinical stage 
(in patients receiving neoadjuvant therapy) and pathologic stage, the majority of patients 
had T1 or T2 (39.0% T1 and 54.6% T2 in the metformin arm, 42.7% T1 and 46.8% T2 
in the placebo arm), and node negative breast cancer (66.7% and 61.4% in the 
metformin and placebo arms, respectively). HER2 amplification was observed in 22.7% 
and 15.8% of the women in the metformin and placebo arms respectively. Ninety-eight 
percent of women had received neoadjuvant or adjuvant chemotherapy.  
 
Baseline SHs measurements 
Estradiol levels were below the assay's lower detection limit of 18.4 pmol/L in 24.1% of 
metformin and 26.2% of placebo patients, Chi-square test p=0.68. As noted above, in 
the primary analysis, the estradiol levels of these cases were set to half the lower 
detection limit, 9.2 pmol/L.  
Baseline SH measurements are shown in Table 2. At baseline the median 
estradiol was 32.2 vs 33.3 pmol/L, SHBG 76.4 vs 72.8 nmol/L and BT 0.02 vs 0.03 
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Change in SHs at six months  
In the main analysis, the median change between baseline and month 6 in estradiol was 
5.7 pmol/L in the metformin arm vs 0 in the placebo arm (Wilcoxon test p<0.001 , 
Table 2). The supplementary analysis supported this result - Figure 2 shows that the 
estradiol exceedance probabilities were consistently lower in the metformin than the 
placebo group (log-rank p<0.001), for example 56.9% vs 71.0% had estradiol levels 
over 20 pmol/L, 19.7% vs 42.6% had estradiol levels over 40 pmol/L and 8.0% vs 
23.1% had estradiol levels over 60 pmol/L, respectively. The multivariable regression 
model estimated that month 6 estradiol was approximately 30.1% (95% CI, 19.0% to 
39.7%) lower in the metformin vs placebo groups. When adjustment for baseline BMI 
and BMI change was added to the basic model, the reduction in estradiol in metformin 
vs placebo subjects was 25.7% (95% CI, 13.2% to 36.4%) and when adjustment for 
change in insulin was added to the basic model this was 30.1% (95% CI, 18.7% to 
39.8%). In addition, examination of the interaction term in the regression model did not 
find evidence that the reduction in estradiol associated with the metformin arm was 
affected by the C allele of the SNP rs11212617 (Figure 3). 
In contrast to estradiol, median changes in SHBG and BT were similar in the 
metformin vs placebo arms (SHBG -5.9 vs. -5.9 nmol/L, p=0.43; BT 0 vs 0 nmol/L, 
p=0.24), as observed in Table 2. 
 
Discussion  
Our observation of a statistically significant decrease in estradiol between baseline and 
month 6 in the metformin arm as compared to placebo is consistent with the work 
published by Campagnoli et al.,5,6 who studied a selected postmenopausal non-diabetic 
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high baseline testosterone levels. In that study, a decrease in estradiol (-38%; p< 0.02) 
and in testosterone (-29%, p< 0.02) was seen in those receiving metformin 1500 mg/day 
(close to the 1700 mg/day administered in MA.32) vs metformin 1000 mg/day. The 
30% reduction in estradiol we identified was similar to that seen by Campagnoli et al. 
Our population differs from that studies by Campagnoli et al. in that our subjects were 
not selected for high baseline levels of testosterone - this difference in entry criteria may 
account for our failure to identify changes in SHBG or BT with metformin. These 
observations suggest that the estradiol change we observed is independent of 
testosterone or of a potential effect of metformin on liver synthesis of SHBG.  
Patterson et al.,7 reported reductions in estradiol, testosterone and SHBG in 
overweight or obese BC patients receiving metformin, however, it was not clear 
whether the small reductions in estradiol that were observed (-10%, 95% CI -18.5 to -
1.5%) in those receiving metformin were due to co-administration of the lifestyle-based 
weight loss intervention. Small changes were also seen in testosterone and SHBG. As 
noted above, metformin had no impact on SHBG, estradiol, testosterone and 
dehydroepiandrosterone in 382 overweight, glucose-intolerant patients enrolled onto the 
Diabetes Prevention Program.13  
Our study is the first to report the independent effect of metformin on estradiol 
in a placebo-controlled trial without co-intervention (tamoxifen or lifestyle 
intervention). The reduction we observed (approximately 30%) is substantial and of 
potential clinical relevance in breast cancer, and possibly in women with hormone 
receptor positive BC, although we did not study whether similar effects would have 
occurred in women receiving hormonal therapies for their BC. Our findings are also 
potentially relevant to other estrogen-sensitive cancers, notably endometrial cancer for 
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prognosis. Should beneficial effects of metformin be seen in our primary efficacy 
analysis in hormone receptor positive BC, we plan to investigate effects of metformin 
on SHs, including estradiol, in this population. The independence of the observed 
reduction in estradiol from baseline BMI, BMI change and insulin change suggests it 
did not occur as a result of loss of fat mass, nor is it associated with an insulin effect.  
The mechanism by which metformin lowered estradiol remains unclear. Pre-
clinical data have suggested that metformin may inhibit aromatase activity, potentially 
accounting for our observed reduction and also suggesting an additional mechanism of 
anti-cancer action of metformin. Both ER positive breast cancer cells and breast adipose 
stromal cells exhibited reductions in aromatase mRNA levels in response to metformin 
treatment via mechanisms involving the suppression of promoter (PII) and P1.3 specific 
transcripts as well as activation of AMPK.18,19  
Strengths of our study include its conduct in the setting of a placebo controlled 
randomized trial in carefully selected postmenopausal women (thereby excluding 
menstrual cycle variability in sex hormones) who were not receiving hormonal therapy 
(thereby excluding potential confounding by these treatments). Limitations include the 
use of a non-highly sensitive estradiol assay – just under 30% of estradiol assays 
yielded results below the lower detection limit. In our primary analyses we assigned an 
estradiol level of half the lower detection limit. We performed an additional sensitivity 
analysis to generate exceedance curves that provided results similar to those obtained in 
our primary analysis. The similarity of our findings using two different methods of 
analysis, one designed specifically for censored values, reduces the likelihood that use 
of a more sensitive assay we would have led to different findings. Furthermore, the 
selection criteria used in this sub-study, particularly the requirement that subjects be on 
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between study arms. Additionally, the p-values reported are not adjusted for multiple 
comparisons, thus the possibility of false positives cannot be excluded.  
In conclusion, metformin lowered estradiol levels, independent of BMI and 
insulin in non-diabetic post-menopausal women with ER and PR negative BC enrolled 
onto MA.32 trial. This observation suggests a new mechanism of metformin action that 
may be relevant in breast and other estrogen mediated cancers.  
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Age, years mean (SD) 58.1 (± 6.9) 57.5 (± 7.9) 
Weight, kg mean (SD) 72.6 (± 14.1) 76.6 (± 17.5) 
BMI, kg/m2 mean (SD) 27.3 (± 5.2) 28.9 (± 6.4) 
Post-menopausal, n (%) 141 (100) 171 (100) 
Receptor status, n (%) 





Her2 status, n (%) 
    Her2 positive 







Any (neo)adjuvant chemotherapy, n (%) 
    Yes 



















N stage, n (%) 
   N0 
   N1 
   N2 
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Table 2: Baseline Sex Hormones measurements and change from baseline to month 6 
on metformin vs placebo arms.  
 
Sex Hormones  Baseline 
Median (Q1, Q3) 
Change1 










Estradiol pmol/L  32.2 (19.0, 45.5) 33.3 (9.2, 56.4) -5.7 (-18.6,0) 0 (-12.6, 14.7) <0.001  
BT nmol/L 0.02 (0.01, 0.05) 0.03 (0.02,0.06) 0 (-0.01, 0.01) 0 (-0.01, 0.02) 0.02 
SHBG nmol/L 76.4 (60.9, 112) 72.8 (48.8, 105) -5.9 (-15.6, 3.0) -5.9 (-17.4, 1.5) 0.43 
*Q1 and Q3 are the 25th and 75th percentiles, SHBG - Sex Hormone Binding Globulin, BT - 
Bioavailable Testosterone 
1 Change calculated with-in patient as month 6 value minus baseline value 
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Figure titles and legends 
 
Figure1: Consort Diagram. 
 
Figure 2: Exceedance curves for estradiol at 6 months, by study arm. The curves 
give the proportion of patients whose estradiol was higher than any chosen cut-off on 
the x-axis, for example, 20% of metformin patients versus 43% of placebo patients had 
estradiol scores over 40 pmol/L.  
Figure 3: Linear regression model for change in estradiol, adjusted for baseline 
estradiol, with treatment (metformin vs placebo) and SNP (Any C vs AA) as 
explanatory variables. 1 EAnyC/EAA denotes the ratio of estradiol levels at month 6 for the 
two SNP levels, adjusted to the same baseline estradiol. 2 Main effects model: log(month 6 
estradiol) - log(baseline estradiol) as outcome and treatment status, SNP status and baseline 
assay level as covariates. The p-value is for the null hypothesis of no SNP effect, which in terms 
of back-transformed results is that the ratio EAnyC/EAA=1.  3 Interaction model: A treatment 
status-by-SNP status interaction was added to the main effects model. The p-value is for the 
null hypothesis of no interaction effect, which in terms of back-transformed results is that 
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Figure 3 
Regression model for estradiol with an overall SNP effect2 
EAnyC/EAA ratio2 in both arms combined P2 
1.00 (0.85 – 1.18) 0.98 







Ratio of two 
treatment arm ratios P3 
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